Brexpiprazole, a serotonin-dopamine activity modulator, is a partial agonist at 5-HT 1A and dopamine D 2 receptors, and antagonist at 5-HT 2A and noradrenaline α 1B and α 2C receptors, all at similar potency. Efficacy of brexpiprazole was evaluated in patients with acutely exacerbated schizophrenia in three short-term, randomized, double-blind, placebo-controlled studies. In a Phase 2 study, patients were randomized to brexpiprazole 0.25 mg (fixed dose), 1.0 ± 0.5 mg, 2.5 ± 0.5 mg, 5.0 ± 1 mg (flexible-dose ranges), placebo, or aripiprazole 15 ± 5 mg. In two Phase 3 studies, patients were randomized to fixed-dose brexpiprazole 0.25 mg, 1 mg, 2 mg, or 4 mg, or placebo. For this review, brexpiprazole 2 mg and 4 mg arms from the Phase 3 studies were combined. Primary efficacy endpoint was change in Positive and Negative Syndrome Scale (PANSS) total score from baseline at week 6; key secondary endpoint was change in Clinical Global Impression-Severity of illness (CGI-S) score at week 6. Primary outcome moderator analyses explored effects of sex, age, race, and illness duration. There were no statistically significant differences vs. placebo in the Phase 2 brexpiprazole and aripiprazole groups for primary and key secondary endpoints. Combined brexpiprazole 2 mg (n = 359) and 4 mg (n = 359) were superior to placebo (n = 358) in change in PANSS total score (least square mean difference from placebo: −5.46, p = 0.0004, and −6.69, p b 0.0001, respectively) and CGI-S (−0.25, p = 0.0035, and −0.38, p b 0.0001, respectively). Changes from baseline in efficacy endpoints were minimal in the 0.25 mg group, while the 1 mg group exhibited suboptimal improvement. No relevant moderators were identified. Meta-analysis of the pivotal studies indicates brexpiprazole 2 mg and 4 mg are effective in treating acute schizophrenia.
Introduction
Treating patients with schizophrenia is complicated by difficult-topredict responses to medication arising from variations between patients (Carbon and Correll, 2014; Correll et al., 2011) . It has long been recognized that individual patients respond heterogeneously (in terms of both efficacy and tolerability) to second-generation antipsychotics (SGAs) (Citrome, 2013) . In fact, meta-analyses and systematic reviews of randomized controlled studies have identified comparatively small variation in efficacy among SGAs (Leucht et al., 2013a) , but larger and more predictable differences in tolerability and safety profiles (Citrome, 2013; De Hert et al., 2011; Leucht et al., 2013a) .
Choosing a treatment for a patient with schizophrenia is a complex decision based on many factors, including symptom type and severity, comorbidities, and previous treatment history (Correll, 2010) . However, few clinically useful predictors of treatment outcome have been identified (Carbon and Correll, 2014) , and limited guidance exists on how to personalize the treatment decision. Factors that can be considered include the duration of untreated illness, non-adherence to antipsychotics, and lack of an early response to treatment (Carbon and Correll, 2014; Samara et al., 2015) . Pooled or meta-analyses of data from across several studies provide adequate power to conduct clinically meaningful moderator and subgroup analyses that have the Schizophrenia Research 174 (2016) [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] potential to help identify opportunities to individualize a novel treatment option to those subgroups of patients with the highest potential to benefit .
The serotonin-dopamine activity modulator brexpiprazole, which was approved in the USA in July 2015 for the treatment of schizophrenia and as an adjunctive therapy to antidepressants for the treatment of major depressive disorder, acts both as a partial agonist at serotonin 5-HT 1A and dopamine D 2 receptors, and as an antagonist at serotonin 5-HT 2A and noradrenaline α 1B and α 2C receptors, all with similar potency (Maeda et al., 2014) . The intrinsic activity of brexpiprazole at D 2 receptors is lower than that of the first commercially available D 2 partial agonist, aripiprazole. Brexpiprazole's activity at D 2 receptors may translate into a reduced potential to induce adverse events (AEs) mediated by agonism at the D 2 receptor (e.g. akathisia, insomnia, restlessness, and nausea) and D 2 antagonist-like AEs (e.g. extrapyramidal symptoms [EPS] , hyperprolactinemia, and tardive dyskinesia) compared with aripiprazole and full D 2 antagonists, respectively (Fleischhacker, 2005; Maeda et al., 2014) . The efficacy and safety of brexpiprazole for the treatment of patients with an acute exacerbation of schizophrenia was confirmed in a Phase 3 program Kane et al., 2015) .
This overview summarizes efficacy data from three short-term, multicenter, randomized, double-blind, placebo-controlled studies (one Phase 2 and two Phase 3) that evaluated the efficacy, safety, and tolerability of brexpiprazole in patients with an acute exacerbation of schizophrenia. Individual efficacy data from the Phase 3 studies were reported previously Kane et al., 2015) . Safety and tolerability data for the Phase 2 study and the combined Phase 3 studies are shown in the supplementary material. Pooled safety and tolerability data across the three short-term, placebo-controlled studies are reported separately (Kane et al., 2016-in this issue).
Methods

Patients
All three studies recruited male and female patients aged 18-65 years with a current Diagnostic and Statistical Manual of Mental Disorders, fourth edition, Text Revision (DSM-IV-TR) diagnosis of schizophrenia who would benefit from hospitalization or continued hospitalization for treatment of an acute exacerbation. Exacerbation in the Phase 2 study was confirmed at screening and baseline by a Positive and Negative Syndrome Scale (PANSS; (Kay et al., 1987) total score ≥ 80 together with a Clinical Global Impression-Severity of illness (CGI-S; (Guy, 1976) score ≥ 4. Patients in the Phase 3 studies had to have a total Brief Psychiatric Rating Scale score ≥ 40 and a score of ≥ 4 on 2 or more of the following BPRS items: hallucinatory behavior, unusual thought content, conceptual disorganization, or suspiciousness, as well as a CGI-S score ≥ 4 (at screening and baseline). Key exclusion criteria were first episode of schizophrenia, DSM-IV-TR Axis I diagnosis other than schizophrenia, substance abuse or dependence in the previous 180 days, or a clinically significant medical condition.
Study design
The Phase 2 study (NCT00905307, STEP 203) was a multicenter, randomized, double-blind, six-arm, placebo-and active-controlled, flexible-dose study (Fig. 1A ). Patients were randomized (1:2:2:2:2:1) to receive double-blind brexpiprazole at a fixed dose of 0.25 mg or flexible doses of 1 ± 0.5 mg, 2.5 ± 0.5 mg, or 5 ± 1 mg, placebo, or aripiprazole 15 ± 5 mg for 6 weeks. Aripiprazole was included to evaluate assay sensitivity. All patients received the target dose at baseline without titration. Non-responders (Clinical Global ImpressionsImprovement (CGI-I; (Guy, 1976) score N 4 ["no change" or "worse"] at weeks 3 and 4) were offered to switch to open-label brexpiprazole but data collected during open-label treatment were not included in the efficacy analyses.
The two Phase 3 studies had similar designs: both were multicenter, randomized, double-blind, placebo-controlled, fixed-dose trials (study 1, NCT01396421, VECTOR; study 2, NCT01393613, BEACON; Fig. 1B ). Methods have been described previously Kane et al., 2015) . In study 1 patients were randomized to brexpiprazole 0.25 mg, 2 mg or 4 mg or placebo (1:2:2:2) and in study 2 patients were randomized to brexpiprazole 1 mg, 2 mg or 4 mg or placebo (2:3:3:3). The low brexpiprazole dose groups (0.25 and 1 mg) were included to evaluate the lower dose range, based on results from Phase 2 studies that had indicated that 1 mg may be the lowest efficacious dose of brexpiprazole; 0.25 mg was not expected to demonstrate efficacy (Thase et al., 2011) . The 0.25 mg and 1 mg groups received that dose from day 1 and throughout the study. The 2 mg and 4 mg groups were titrated from 1 mg/day to 2 mg/day on day 5 and then, as appropriate, to 4 mg/day on day 8.
In all three studies, blocks of randomization numbers based on a pregenerated permuted-block randomization schedule were assigned to each study center using an interactive voice or web response system. Eligible patients were sequentially assigned a randomization number corresponding to one of the treatment groups. Blinding was assured by restricting access of sponsor personnel to the treatment code and providing identical tablets and packaging for brexpiprazole and placebo. In the Phase 2 study, a double dummy technique was used since aripiprazole differed in appearance from the brexpiprazole and placebo tablets.
In the Phase 2 study, stable patients could, at the discretion of the investigator, be treated as outpatients after week 3. In the Phase 3 studies, patients were hospitalized throughout the double-blind treatment period.
All studies were conducted in compliance with the International Conference on Harmonization Good Clinical Practice Consolidated Guideline. Protocols were approved by independent ethics committees. After complete description of the study to the patients, written informed consent was obtained.
Efficacy assessments
In all studies, efficacy was assessed using the PANSS, CGI-S, CGI-I, and Personal and Social Performance (PSP) scales (Morosini et al., 2000) . The primary efficacy endpoint was change from baseline at week 6 in PANSS total score. Secondary efficacy endpoints for all studies were change from baseline at week 6 in CGI-S (key secondary endpoint); change from baseline at weeks 1-5 in PANSS total score and CGI-S; and change from baseline at week 6 in PSP scale score and in positive and negative symptom PANSS subscale scores; CGI-I at week 6; responder rates (defined as change from baseline in PANSS total score ≥ 30% or CGI-I score of 1-2 at week 6); and discontinuation rate due to lack of efficacy. Additional secondary endpoints for the Phase 3 studies only were change from baseline at week 6 in PANSS Excited Component score (Montoya et al., 2011) and in the five PANSS Marder factor scores (Marder et al., 1997) .
Safety assessments
The safety population comprised all patients who received at least one dose of study medication. Incidence of treatment-emergent adverse events (TEAEs) and mean change from baseline to the last study visit in EPS rating scales, weight, prolactin, and fasting metabolic parameters were combined for the two Phase 3 studies.
Statistical analysis
The efficacy population comprised all patients who received at least one dose of study medication and had both a baseline assessment and ≥ 1 post-randomization efficacy assessment during the double-blind treatment period. Data from the Phase 2 study are reported separately.
Data for the 2 mg and 4 mg brexpiprazole and placebo groups were combined. The two lower doses in the Phase 3 studies (0.25 mg and 1 mg) were not included in pre-specified primary analyses of Phase 3 studies and were excluded from the meta-analysis; their data are reported separately.
The protocol-specified analysis for the primary endpoint (change from baseline to week 6 in PANSS total score) in the Phase 2 study was analysis of covariance (ANCOVA) based on the last observation carried forward (LOCF) dataset. However, mixed model for repeated measures (MMRM) analysis was applied as described for the Phase 3 studies below to facilitate comparison of data across studies. For patients who received open-label brexpiprazole, data from the last visit prior to initiation of open-label treatment were carried forward to week 6. The Hochberg procedure (Hochberg and Tamhane, 1987) using a two-sided alpha of 0.05 was used to control the type I error rate due to multiple comparisons.
For the combined Phase 3 data, the primary efficacy endpoint, change from baseline at week 6 in PANSS total score, was analyzed using MMRM. The model included fixed-effect factors of study, site nested within study, treatment, visit, and treatment-by-visit interaction, and fixed-effect covariates of baseline score and baseline-by-visit interaction. Least squares mean differences between brexpiprazole and placebo derived from the MMRM analysis were tested statistically. The key secondary efficacy endpoint, change from baseline at week 6 in CGI-S score, was analyzed using the same MMRM model. MMRM analysis was also applied to changes from baseline in PSP scale score, PANSS subscale scores, PANSS Excited Component score, and PANSS Marder factor scores. CGI-I score at week 6 was analyzed using the Cochran-Mantel-Haenszel (CMH) row mean scores test (Davis and Chung, 1995) , controlling for site; responder rate (mean change from baseline in PANSS total score of ≥ 30% or CGI-I score of 1 or 2 [very much improved or much improved] at week 6) and discontinuation rates due to lack of efficacy were analyzed by the CMH general association test (Cochran, 1954) .
Pre-planned treatment-by-subgroup interaction analyses by age (b 55 years; ≥ 55 years), sex (male; female), and race (white; other races) were performed using the MMRM for change from baseline at week 6 in PANSS total score.
Post-hoc analyses included responder rates based on ≥ 20%, ≥ 40%, and ≥50% reductions in PANSS total score or a CGI-I score of 1 or 2 at week 6 (as defined in the two Phase 3 studies Kane et al., 2015) ) for combined brexpiprazole 2 mg, 4 mg, and placebo groups; MMRM analysis of change from baseline at week 6 in individual PSP items: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behaviors; regression analysis derived from a model of mean change from baseline at week 6 in PANSS total score with factors of disease duration and treatment; and MMRM analysis of change from baseline at week 6 in PANSS total score for duration of illness subgroups defined by tertiles to ensure adequate patient numbers in each subgroup. In addition, for the combined Phase 3 data, Cohen's d-effect sizes for the primary and key secondary efficacy endpoints were calculated as treatment-placebo difference divided by pooled standard deviation with 95% confidence intervals derived using the delta method. Number-needed-to-treat (NNT) for responder rates was calculated as 100 divided by the absolute risk reduction.
Results
Patients
Overall, 268/459 (58.4%) patients completed the Phase 2 study, with a greater proportion of completers in the 1 ± 0.5 mg, 2.5 ± 0.5 mg, or 5 ± 1 mg brexpiprazole and aripiprazole groups than placebo ( Fig. 2A) .
Patients included in the meta-analysis were randomized to brexpiprazole 2 mg (n = 368), 4 mg (n = 364), or placebo (n = 368) [ Fig. 2B ]. More patients completed the study in the combined brexpiprazole groups than with placebo (2 mg: 68.8%; 4 mg: 69.0%; placebo: 61.7%). The efficacy population included 359, 359, and 358 patients in the combined brexpiprazole 2 mg, 4 mg, and placebo groups, respectively. Patient disposition for the brexpiprazole 0.25 mg and 1 mg groups is shown in Fig. 2B .
Demographic and baseline clinical characteristics were similar across all treatment groups (Tables 1A and 1B) .
Positive and negative syndrome scale total score (primary efficacy endpoint)
In the Phase 2 study, none of the active groups (brexpiprazole or aripiprazole) were significantly different from placebo for change from baseline in PANSS total score at week 6 (Table 2A) , although changes from baseline in all active groups were similar and numerically greater than placebo. Additionally, none of the active groups met the primary efficacy endpoint in the protocol-specified analysis (ANCOVA on LOCF), as none of the brexpiprazole treatment groups achieved p b 0.05 compared with placebo (p = 0.2263, p = 0.0949, p = 0.6066, and p = 0.1646 for the 0.25 mg, 1.0 ± 0.5 mg, 2.5 ± 0.5 mg, and 5.0 ± 1.0 mg treatment groups, respectively).
In the Phase 3 studies, while the 2 mg arm was not statistically different from placebo in study 2 , the combined 2 mg and 4 mg groups showed statistically significantly greater improvements from baseline at week 6 in PANSS total score compared with placebo (p = 0.0004 and p b 0.0001, Cohen's d effect size 0.27 and 0.33, respectively; Table 2B ). In both groups, a significant treatment effect was apparent at week 1 and was maintained throughout the treatment period (Fig. 3A) . Changes from baseline at week 6 were minimal in the 0.25 mg group, while the 1 mg brexpiprazole group exhibited a suboptimal response that was less than that for either 2 mg or 4 mg (Table 2B) .
Secondary efficacy endpoints
In the Phase 2 study, numerically greater improvements from baseline were seen in the flexible-dose brexpiprazole and aripiprazole groups compared with placebo for some of the secondary efficacy endpoints (Table 2A ).
In the Phase 3 studies, the combined brexpiprazole 2 mg and 4 mg groups were different from placebo for the key secondary efficacy endpoint, mean change from baseline at week 6 in CGI-S total score (Table 2B , Figs. 3B and 4). Brexpiprazole 2 mg and 4 mg consistently showed greater improvement compared with placebo (p b 0.05) in all other secondary endpoints, with the exception of discontinuation rate due to lack of efficacy in the combined 2 mg group (Table 2B) . NNTs for response ≥ 30% improvement to brexpiprazole 2 mg and 4 mg were 9 and 6, respectively. A post-hoc analysis showed improvements (p b 0.05 vs. placebo) in all individual PSP scale items in the brexpiprazole 4 mg group, and improvements in socially useful activities and self-care in the 2 mg group (Fig. 5) .
Brexpiprazole 0.25 mg and 1 mg demonstrated less improvement over placebo in the secondary efficacy endpoints, consistent with the primary endpoint (Table 2B) .
Subgroup analyses
For the primary efficacy endpoint, no treatment-by-subgroup interactions were found for age or sex for any of the combined or individual treatment groups. There was also no treatment-by-subgroup interaction for race in the combined 2 mg group and all the Phase 2 study groups. In the combined 4 mg group, the change from baseline at week 6 in PANSS total score was smaller in Caucasian patients than in those of other races (interaction by race, p = 0.0328), but the difference between brexpiprazole and placebo was statistically significant for both Correll et al. (2015) ; Kane et al. (2015) . b Placebo, brexpiprazole 2 mg, and brexpiprazole 4 mg groups are combined from studies 1 and 2. Bold text indicates p b 0.05 compared with placebo. For the Phase 3 studies, combined brexpiprazole 2 mg and 4 mg groups are compared with the combined placebo group. Brexpiprazole 0.25 mg and 1 mg groups are compared with the placebo groups from the individual studies. CGI-I, Clinical Global Impressions -Improvement; CGI-S, Clinical Global Impressions -Severity of illness; CI, confidence interval; CMH, Cochran-Mantel-Haenszel; LS, least squares; NA, not available; NNT, number needed-to-treat; PANSS, Positive and Negative Syndrome Scale; PSP scale, Personal and Social Performance scale; SE, standard error. a LS mean (SE) change from baseline at week 6; p-value (brexpiprazole vs. placebo) is derived from a mixed-model repeated measures analysis. b p-value (brexpiprazole vs. placebo) derived from CMH row mean scores differ test. c Defined as mean change from baseline in PANSS total score ≥ 30% (protocol-defined) or ≥20%, ≥40%, or ≥50% (post hoc) or CGI-I score of 1 (very much improved) or 2 (much improved) at week 6. d p-value (brexpiprazole vs. placebo) derived from CMH general association test. e NNT could not be calculated as the responder rate was higher in the placebo group than the brexpiprazole group. f Correll et al. (2015) ; Kane et al. (2015) . g Placebo, brexpiprazole 2 mg, and 4 mg groups were combined from studies 1 and 2. h Statistical analysis was exploratory for all parameters; treatment differences and p-values were obtained from the individual studies. i Marder et al. (1997) .
Caucasian patients (− 4.61, p = 0.0213) and other races (− 11.22, p b 0.0001).
Post-hoc analyses by duration of illness
Regression analysis showed a weak, but statistically significant, negative association between reduction in PANSS total score and duration of illness (r = 0.18, p = 0.0049). Grouping illness duration in tertiles, in the combined 2 mg brexpiprazole group, the response was greater in patients with shorter duration of illness. In contrast, consistent efficacy was seen across all tertiles in the combined 4 mg group (Table 3) .
Safety and tolerability
Safety data for the Phase 2 study and the combined Phase 3 studies are shown in the supplementary material, including the incidence of TEAEs (Table S1 ) and the mean change from baseline to the last study visit in EPS rating scales (Table S2) , weight, prolactin, and fasting metabolic parameters (Table S3 ).
Discussion
The short-term efficacy of brexpiprazole for the treatment of patients with an acute exacerbation of schizophrenia was evaluated in one Phase 2 and two similarly designed Phase 3 studies. The Phase 2 study did not meet its primary efficacy endpoint because change from baseline at week 6 in PANSS total score did not differ significantly from placebo in any of the brexpiprazole groups. However, the active control aripiprazole group did not separate from placebo either, indicating a lack of adequate assay sensitivity. It is likely that this study failed because of the relatively high placebo response (which is not unusual in studies with multiple active treatment arms, especially in more recently conducted studies (Agid et al., 2013) , which may have obscured true treatment-related benefits. However, numerical improvements in psychiatric scale scores at week 6 were observed in all flexible-dose brexpiprazole groups vs. placebo, suggesting that dosages of brexpiprazole between 1 mg/day and 5 mg/day may be effective in this population. Since data indicated that the incidence of akathisia increased at doses above 4 mg (Kane et al., 2016-in this issue), the 5 mg dose was not used in the Phase 3 trials. However, one needs to consider that, in the Phase 2 study, the 5 mg dose was started without any titration whereas patients in the Phase 3 trials initiated treatment at 1 mg for 4 days, followed by 2 mg at day 5 and 4 mg at day 8 Kane et al., 2015) . Whether brexpiprazole could be started safely at 2 mg and whether doses higher than 4 mg could be well tolerated and effective in patients receiving suboptimal benefits from 4 mg should be determined in future studies.
Meta-analysis of two Phase 3 studies demonstrated that brexpiprazole 2 mg and 4 mg were effective in adults with an acute exacerbation of schizophrenia, as evidenced by superiority over placebo in both the primary efficacy endpoint, change in PANSS total score, and the key secondary efficacy endpoint, change in CGI-S. Brexpiprazole 2 mg and 4 mg also showed significantly greater improvement compared with placebo in most other secondary efficacy endpoints, including PSP scale, positive and negative PANSS subscales, PANSS Excited Component score, responder rates, and PANSS factor scores as defined by Marder et al. (Marder et al., 1997) . Although many elements contribute to disability in schizophrenia, it is known that expression of prominent symptoms is associated with functional impairment (Rabinowitz et al., 2013) .
Brexpiprazole had a positive effect on social and personal functioning in the PSP scale domains of socially useful activities, relationships, selfcare, and disturbing and aggressive behavior, perhaps reflecting its ability to reduce symptoms. Subgroup analyses indicated that brexpiprazole had a consistent effect on PANSS total score across male and female patients, older and younger patients (≥ 55 vs. b 55 years), and different races (Caucasian vs. other races), suggesting that these symptom-related benefits are not limited to specific patient subgroups. Treatment effects were also seen in patients with early and late stages of illness.
Despite the availability of a range of SGAs with various mechanisms of action, schizophrenia remains a difficult condition to treat. Brexpiprazole has a high affinity for 5-HT 1A and 5-HT 2A receptors that is similar to its affinity at D 2 receptors and higher than that of aripiprazole (Maeda et al., 2014) . This balanced binding profile may provide additional clinical benefits, because 5-HT 2A antagonism is thought to contribute to antipsychotic activity (Ebdrup et al., 2011) , and contribute to a balanced safety profile, because 5-HT 2A antagonism is thought to counter EPS and akathisia (Kane et al., 2016-in this issue; (Laoutidis and Luckhaus, 2014) . Brexpiprazole also has a moderately low relative affinity for receptors (e.g. H 1 histamine receptors) that have been associated with sedation (Maeda et al., 2014) . The safety data from the pooled Phase 3 studies indicate that brexpiprazole is well tolerated with a low incidence of EPS-related TEAEs and akathisia as well as a low incidence of sedation and somnolence, reflecting its pharmacological profile.
In the pivotal 4-to 6-week, double-blind, placebo-controlled clinical trials in patients with acute exacerbations of schizophrenia, aripiprazole 10-30 mg/day significantly reduced mean PANSS score from baseline by 11 to 16 points, compared with a reduction of 2 to 5 points in the placebo groups (Cutler et al., 2006; Kane et al., 2002; McEvoy et al., 2007; Potkin et al., 2003) . Although direct comparisons of studies with different methodologies should be made with caution, the brexpiprazoleplacebo difference from the meta-analysis results reported here appear to be in the same range as those of aripiprazole. However, it should be noted that the improvement seen with placebo was more than double that seen in the aripiprazole studies (mean PANSS total score reduction of 12 points with placebo compared with 18 and 20 points with brexpiprazole). An increasing placebo response over time has been observed before (Agid et al., 2013; Alphs et al., 2012) , having resulted in smaller effect sizes in antipsychotics studied more recently (Correll and De Hert, 2013) . In addition, NNTs and effect sizes have been used to provide an indirect comparison of different SGAs, although this approach is limited by differences between studies in the placebo response (Huhn et al., 2014; Leucht et al., 2013b) and the definition of response (Leucht, 2014) . From the combined Phase 3 studies, NNTs for protocol-defined responder rate for brexpiprazole 2 mg and 4 mg Fig. 4 . Estimated treatment effects for change from baseline at week 6 in Clinical Global Impressions -Severity of illness score (efficacy population). Combined brexpiprazole 2 mg and 4 mg groups are compared with the combined placebo group. Phase 2 brexpiprazole groups and Phase 3 brexpiprazole 0.25 mg and 1 mg groups are compared with the placebo groups from the individual studies. ARIP, aripiprazole; BREX, brexpiprazole; LCL, lower confidence limit; LSMD, least squares mean difference; UCL, upper confidence limit. were 9 and 6-7, respectively; these values are in the same range as the reported NNT values for olanzapine (NNT = 7) and risperidone (NNT = 8) and numerically better than those for aripiprazole (NNT = 10) and quetiapine (NNT = 10) (Leucht et al., 2013a) . Similarly, effect sizes were within the range of those reported for other antipsychotics (Leucht et al., 2013a) . The finding that combined effect sizes for the change in PANSS total scores were in the lower range of those reported in the recent network meta-analysis (Leucht et al., 2013a ) is influenced by the fact that the combined placebo response across the two brexpiprazole studies was relatively high, yet in one of the two studies , the effect size (0.4) was in the mid-range of the ranking in the network meta-analysis.
One limitation of the current analyses is the absence of an active comparator in the Phase 3 trials. However, this meta-analysis indicates that brexpiprazole 2 mg and 4 mg are effective for the treatment of adults with acute exacerbation of schizophrenia, as evidenced by results obtained from two Phase 3 placebo-controlled studies.
Additional long-term and real-world clinical data will be important to fully evaluate the value of brexpiprazole for treating patients with schizophrenia. While the lower, ineffective brexpiprazole dose range of 0.25-1 mg has been clarified in schizophrenia, as mentioned above, titration and the upper dose range should be explored further. Efficacy data cannot be judged in isolation so it is important that pooled safety data from the short-term studies and two open-label long-term studies have indicated that brexpiprazole is well tolerated in adults with schizophrenia (Kane et al, 2016-in press ).
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Table 3
Change from baseline to week 6 in PANSS total score by tertiles of duration of illness for the combined Phase 3 studies (efficacy population).
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